PTGS2 and non-small cell lung carcinoma: It has been reported that PTGS2 potentiated cisplatin resistance of NSCLC by promoting the epithelial–mesenchymal transformation (EMT) through activation of the AKT signaling pathway (Jiang et al., 2019).